Ilonov is harnessing groundbreaking discoveries to revolutionize treatment for metabolic disorders. By harvesting novel targets discovered from breakthrough research on the human muscle secretome, the company is developing first-in-class therapies dedicated to the treatment of diabetes and metabolic diseases
Ilonov is a spin off of the European center for diabetes studies (CeeD) in Strasbourg, France founded Dr. Karim Bouzakri, Prof. Michel Pinget, and Dr. Anastasia Grabarz.
Ilonov’s asset plays a pivotal role in skeletal muscle‐to‐pancreas interorgan communication allowing to preserve & restore pancreatic beta cell function. Through its action on the extracellular matrix it maintains islet structure together with intraislet signaling pathways allowing to strongly limit inflammation and maintain mitochondrial function.
Moreover, it has shown safety and efficacy in type 1 and 2 diabetic models in vivo.
Ilonov aims at quickly advancing its pipeline of first-in-class biotherapeutics and has recently entered into a research collaboration agreement with a leading pharmaceutical partner.
We look forward to seeing Ilonov’s advancements shape the future of metabolic disease treatment.
